Search

Your search keyword '"Umberto Vespasiani-Gentilucci"' showing total 179 results

Search Constraints

Start Over You searched for: Author "Umberto Vespasiani-Gentilucci" Remove constraint Author: "Umberto Vespasiani-Gentilucci"
179 results on '"Umberto Vespasiani-Gentilucci"'

Search Results

1. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

2. Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication

3. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver

4. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank

5. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

6. The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period

7. Steroid-refractory immune related hepatitis may hide viral re-activation

8. Lipophagy Impairment Is Associated With Disease Progression in NAFLD

9. Voltammetric analysis for distinguishing portal hypertension-related from malignancy-related ascites: A proof of concept study.

10. Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study

11. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin

12. The Liver as Another Possible Target Organ for Bacillus cereus Infection

13. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology.

14. Hypoalbuminemia and Risk of Portal Vein Thrombosis in Cirrhosis

15. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures

16. The authors reply

17. Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

18. Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

19. Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management

20. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank

21. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

22. Reply

23. Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients

24. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis

25. Reply

26. Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers

27. Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry

28. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

29. Issue Cover

30. Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment

31. Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease

32. Machine learning in primary biliary cholangitis: A novel approach for risk stratification

33. Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry

34. Relation between drug therapy-based comorbidity indices, Charlson's comorbidity index, polypharmacy and mortality in three samples of older adults

35. Global multi-stakeholder endorsement of the MAFLD definition

36. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

37. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery

38. Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

39. Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients

40. Exhaled breath analysis in hepatology: State-of-the-art and perspectives

42. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

43. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver

44. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores

45. Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients

46. What changed in the Italian internal medicine and geriatric wards during the lockdown

47. Initiation of Psycholeptic Medication During Hospitalization With Recommendation for Discontinuation After Discharge

48. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

49. Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients

50. Comparison between drug therapy-based comorbidity indices and the Charlson Comorbidity Index for the detection of severe multimorbidity in older subjects

Catalog

Books, media, physical & digital resources